<DOC>
	<DOCNO>NCT01490866</DOCNO>
	<brief_summary>This non-randomized , open-label , Phase II trial investigate axitinib single-agent maintenance therapy follow standard first-line FOLFOX/bevacizumab therapy patient mCRC .</brief_summary>
	<brief_title>A Trial Single Agent Axitinib Maintenance Therapy Patients With First Line Metastatic Colorectal Cancer ( mCRC )</brief_title>
	<detailed_description>All patient receive FOLFOX/bevacizumab four 28-day cycle ( total 16 week ) . After 4 cycle , maintenance axitinib start . With approval Medical Monitor , patient significant benefit FOLFOX/bevacizumab may continue chemotherapy maximum six 28-day cycle . During trial treatment , patient assess response every 8 week ( 2 cycle ) .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<criteria>Histologically cytologically confirm metastatic adenocarcinoma colon rectum . Patients must measurable disease per RECIST Version 1.1 . No previous systemic therapy metastatic colorectal cancer . Previous radiosensitizing chemotherapy allow , complete least 4 week prior Cycle 1 Day 1 study treatment , previous neoadjuvant and/or adjuvant chemotherapy allow , complete least 6 month prior diagnosis metastatic disease . Eastern Cooperative Oncology Group ( ECOG ) Performance Status score 0 1 . Life expectancy &gt; =12 week . Adequate hematologic , renal hepatic function Patients coumadin INR value within therapeutic range ( i.e. , 2 3 x ULN ) . Patients stable , chronic dos coumadin eligible . Male patient willing use adequate contraceptive measure . Female patient childbearing potential , female patient childbearing potential agree use adequate contraceptive measure , breastfeeding , negative serum urine pregnancy test perform within 72 hour prior start treatment . Willingness ability comply trial followup procedure . Ability understand investigative nature trial give write informed consent . History know presence central nervous system ( CNS ) metastasis . Patients major surgical procedure ( include mediastinoscopy ) , significant traumatic injury &lt; =4 week prior begin treatment . Women pregnant lactating . All female childbearing potential must negative serum urine pregnancy test within 72 hour prior study treatment ( see Appendix D ) History hypersensitivity active inactive excipients component treatment ( 5 fluorouracil , bevacizumab , oxaliplatin , axitinib ) , know dipyrimidine dehydrogenase deficiency . Patients proteinuria screen demonstrate : Urine dipstick proteinuria &gt; =2+ ( patient discover &gt; =2+ proteinuria dipstick urinalysis baseline undergo 24hour urine collection , must demonstrate &lt; =1 g protein/24 hour eligible ) Patients serious non healing wound , active ulcer , untreated bone fracture . Patients evidence bleed diathesis significant coagulopathy ( absence therapeutic anticoagulation ) . Patients history hematemesis hemoptysis ( define bright red blood Â½ teaspoon per episode ) &lt; =1 month prior study enrollment . Patients require concomitant treatment potent CYP3A4 CYP1A2 inducer CYP3A4 inhibitor . History myocardial infarction unstable angina &lt; =6 month prior begin treatment . Inadequately control hypertension ( define systolic blood pressure &gt; 150 mmHg and/or diastolic blood pressure &gt; 100 mmHg antihypertensive medication ) . Initiation antihypertensive agent permit provided adequate control document least 1 week prior Day 1 study treatment . New York Heart Association Grade II great congestive heart failure . Serious cardiac arrhythmia require medication . Patients chronic , ratecontrolled atrial fibrillation eligible . Significant vascular disease ( e.g. , aortic aneurysm require surgical repair , recent peripheral arterial thrombosis ) &lt; =6 month prior Day 1 treatment . History stroke transient ischemic attack &lt; =6 month prior begin treatment . Any prior history hypertensive crisis hypertensive encephalopathy . History abdominal fistula gastrointestinal perforation &lt; =6 month prior Day 1 begin treatment . Concurrent severe , intercurrent illness include , limited , ongoing active infection , psychiatric illness/social situation would limit compliance study requirement . Any known positive test human immunodeficiency virus , hepatitis C virus acute chronic hepatitis B infection . Mental condition would prevent patient comprehension nature , risk associate , study . Use nonapproved investigational agent &lt; =28 day prior administration first dose study drug . Patients may receive investigational anticancer treatment participate study . Past current history neoplasm entry diagnosis exception treat nonmelanoma skin cancer carcinoma situ cervix , cancer cure local therapy alone disease free survival &gt; =5 year . Infection require IV antibiotic . Impairment gastrointestinal function gastrointestinal disease may significantly alter drug absorption ( e.g . active inflammatory bowel disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome significant small bowel resection ) . Inability swallow whole tablet . Patients &gt; Grade 2 peripheral neuropathy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Colorectal Cancer</keyword>
	<keyword>Axitinib</keyword>
	<keyword>FOLFOX/Bevacizumab</keyword>
</DOC>